跳至主要内容
临床试验/EUCTR2006-000137-35-LT
EUCTR2006-000137-35-LT进行中(未招募)不适用

Prospective controlled clinical trial of metastatic breast cancer treatment with capecitabine/docetaxel in combination with beta epoetin as compared with sole capecitabine/docetaxel treatment

AB Roche Lietuva0 个研究点目标入组 60 人开始时间: 2006年2月27日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • 1. Form of informed individual consent signed prior to applying any specific trial selection procedure
  • 2. Patients willing and capable to follow the requirements indicated in the protocol
  • 3. Patients older than 18 years
  • 4. Histologically confirmed metastatic breast carcinoma
  • 5. Patients having no contraindications against capecitabine/docetaxsel treatment
  • 6. Hb = 110g/l
  • 7. Grade according to ECOG Performance Status: 0-2
  • 8. Estimated term of life = 6 months
  • 9. Agreement of pre-menopausal patients to use contraceptives during the trial terms
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Other malignant tumours during the last 5 years (other than completely treated basal cells and (or) squamous cell skin carcinoma (or) squamous cell skin carcinoma and (or) cervical in situ carcinoma)
  • 2. Pregnancy (positive serum pregnancy test) and breast feeding
  • 3. Earlier or detected during inspection disease of CNS (e.g., primary brain tumour, seizures not controllable by standard drug medication, any brain metastases)
  • 4. Clinically significant heart disease, not controllable by drug medication:
  • 4.1. Heart insufficiency, symptomatic coronary heart disease or heart arrhythmia (NYHA class 3 or 4, see. Appendix III)
  • 4.2. Myocardial infarction during the last 12 months
  • 4.3. Treatment resistant hypertension
  • 5. Peripheral neuropathy = 1 grade
  • 6. Transfusion of erythrocyte mass during the last month prior to involvement into clinical trial
  • 7. Anaemia not related directly to chemotherapy and (or) tumour itself
  • 7.1. Iron deficiency anaemia (Fe < LLN or feritine <10 µg/l), which can not be corrected with iron supplements
  • 7.2. Vitamin B12 deficiency anaemia (MCV >105 fL and/or vitamin B12 concentration < LLN), which can not be corrected with vitamin B12
  • 7.3. Folic acid deficiency anaemia (MCV >105 fL and/or folic acid concentration < LLN), which can not be corrected with folic acid preparations
  • 7.4. Haemolytic anaemia (laboratory indications of haemolysis: reticulocytes > ULN and indirect bilirubine >ULN ± LDH > ULN)
  • 8. Any laboratory indication value as given below:
  • 8.1. General blood test: number of neutrophils < 1,5 x 109/l, number of thrombocites < 50 x 109/l,
  • 8.2. Biochemical blood test: total bilirubine > 1,5 x upper norm limit (ULN), ASAT, ALT > 2,5 x ULN, alkaline phosphatase > 2,5 x ULN, serum creatinine > 1,5 x ULN or creatinine clearance = 50 ml/min (calculated according to Cockroft and Gault formula or formula presented in the internet web page: http://www.globalrph.com/crcl.htm)
  • 9. Present or recent (28 days prior to randomisation) uptake of another trial drug or participation in another clinical trial
  • 10. Thrombophylia detected by anamnesis and/or clinically confirmed deep venous thrombosis
  • 11. Acute or chronic bleeding requiring treatment during the last month

研究者

发起方
AB Roche Lietuva

相似试验